NCT03335267View on ClinicalTrials.gov

Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

October 19, 2017

Primary Completion Date

December 19, 2018

Study Completion Date

May 29, 2020

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

CPX-351

Cytarabine:Daunorubicin Liposome Injection

Trial Locations (1)

10021

Weill Cornell Medical College, New York

Sponsors

Collaborators (1)

Jazz Pharmaceuticals

All Listed Sponsors

collaborator

Jazz Pharmaceuticals

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER